Assess whether to resubmit, meet, or pause the program (c8533a)

SITUATION In a labeling team facing a boxed-warning debate, scientific-advice briefing book is the evidence after a boxed-warning proposal from the review division. Pharmacovigilance medical reviewer has to pick To resubmit, meet, or Pause the program for this Pharma & Life Sciences Pharmacovigilance close using scientific-advice briefing book.

DECISION Pharmacovigilance medical reviewer in a labeling team facing a boxed-warning debate must choose To resubmit, meet, / Pause the program using scientific-advice briefing book after a boxed-warning proposal from the review division.

HYPOTHESES TO TEST 1. Authorize To resubmit, meet, now; scientific-advice briefing book already has the discriminator after a boxed-warning proposal from the review division. 2. Keep Pause the program in force until scientific-advice briefing book is completed after a boxed-warning proposal from the review division for pharmacovigilance medical reviewer. 3. Treat scientific-advice briefing book as To resubmit, meet, because both readings appear after a boxed-warning proposal from the review division. 4. Refuse a Pharma & Life Sciences close: pharmacovigilance medical reviewer does not have the decision to resubmit, meet, or turns on in scientific-advice briefing book.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in scientific-advice briefing book after a boxed-warning proposal from the review division. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on to resubmit, meet, or. 4. For this Pharma & Life Sciences Pharmacovigilance file, read scientific-advice briefing book against a boxed-warning proposal from the review division and write the one fact that would move to resubmit, meet, or for pharmacovigilance medical reviewer.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / Pharmacovigilance packet (scientific-advice briefing book after a boxed-warning proposal from the review division). The follow-on Pharmacovigilance action is what pharmacovigilance medical reviewer does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in scientific-advice briefing book, then the action for pharmacovigilance medical reviewer - Hypothesis scorecard against scientific-advice briefing book: supported / rejected / untestable - Owner and next date for pharmacovigilance medical reviewer in a labeling team facing a boxed-warning debate - What changes to resubmit, meet, or if a boxed-warning proposal from the review division is later withdrawn